Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma. (6th January 2019)

• Record Type: Journal Article
• Authors: Chu, Yaya; Gardenswartz, Aliza; Termuhlen, Amanda M.; Cairo, Mitchell S.
• Other Names: Cairo Mitchell S. guestEditor.
• Is Part Of: British journal of haematology. Volume 185:Number 6(2019)
• Page Start: 1055
• Page End: 1070
• Publication Date: 2019-01-06
• Subjects: cellular immunotherapy -- chimeric antigen receptor -- B‐cell non‐Hodgkin lymphoma -- stem cell transplantation -- IL‐15 superagonist; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15753
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral‐derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.